

# BAR & BENCH

THE NEW FACE OF LEGAL JOURNALISM IN INDIA

Bar & Bench / January 5, 2017 / Dealstreet

## Cyril Amarchand, NDA lead on Zydus Cadila acquisition of 6 brands from Merck India

Ahmedabad-based drug maker Zydus Cadila has acquired six brands from the Indian unit of US pharmaceutical giant Merck for an undisclosed amount.

<b>Deal</b>	Zydus Cadila acquires six brands from Merck
-------------	---

<b>Value</b>	NA
--------------	----

<b>Deal Type</b>	M&A
------------------	-----

<b>Sector</b>	Healthcare
---------------	------------

<b>Law Firms</b>	<b>Cyril Amarchand Mangaldas</b> – Zydus Cadila; <b>Nisith Desai Associates</b> – Merck
------------------	---

<b>Partners/Heads</b>	Cyril Amarchand Mangaldas – <b>Smruti Shah</b> and <b>Anshuman Sakle</b> ; Nishith Desai Associates – <b>Gowree Gokhale</b>
-----------------------	---

**Cyril Amarchand Mangaldas** advised Zydus Cadila with a team led by Mumbai based corporate partner **Smruti Shah** along with competition law partner **Anshuman Sakle**.

**Nishith Desai Associates** advised Merck and the team included Partner **Gowree Gokhale**, Senior Associate Aarushi Jain and Associate Pooja Kapadia.

Zydus has acquired Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten from Merck Sharp and Dohme (MSD). These brands fall in the men's and women's health, wound management and cardiovascular therapy segments.